HQP1351

DB16185InvestigationalSmall molecule

HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).

Mechanism: Pharmacologically active on Tyrosine-protein kinase ABL1, Receptor-type tyrosine-protein kinase FLT3, and Mast/stem cell growth factor receptor Kit
Curator reviewed
Formula / weight: C₂₉H₂₇F₃N₆O · 532.571 g/mol (avg)
Also known as: Hqp-1351 free base · Hqp1351 free base · Olverembatinib
Code names: D-824 · GZD-824 · HQP-1351

Resolves to

Compound

UNIIKV1M7Q3CBPCAS1257628-77-5ChEMBLCHEMBL2316582

Structure

InChIKeyTZKBVRDEOITLRB-UHFFFAOYSA-NSMILESCN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CC5=C(NN=C5)N=C4)=C(C)C=C3)C=C2)C(F)(F)F)CC1

Targets

P00519ABL1P36888FLT3P10721KITP12931SRCP16234PDGFRAP11362FGFR1

What you can answer from here — as of July 08, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

37Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with HQP1351, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account